Results 1 to 8 of 8
Page 1 of 1
TypeTitleAuthor(s)YearViews
eGFR improvement in chronic hepatitis b patients with telbivudine treatment is independent of antiviral activityGane, EJ; Liaw, YF; Wang, Y; Lai, CL; Rasenack, J; Zeuzem, S; Chan, HLY; Ren, H; Dong, Y; Uddin, A; Jung, ME; Bosset, S; Trylesinski, A201330
 
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis BLiaw, Y; Gane, E; Leung, N; Zeuzem, S; Wang, Y; Lai, CL; Heathcote, EJ; Manns, M; Bzowej, N; Niu, J; Han, S; Hwang, SG; Cakaloglu, Y; Tong, MJ; Papatheodoridis, G; Chen, Y; Brown, NA; Albanis, E; Galil, K; Naoumov, NV20091,845
 
Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patientsHsu, CW; Chen, YC; Liaw, YF; Gane, E; Manns, M; Zeuzem, S; Wang, Y; Lai, CL; Hou, J; Leung, N; Bzowej, N; Niu, J; Jia, J; Hwang, SG; Cakaloglu, Y; Ren, H; Papatheodoridis, G; Chen, Y; Bao, W; Lopez, P2009322
 
Telbivudine versus lamivudine in patients with chronic hepatitis BLai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV; Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G; Constance, BF; Brown, NA2007257
 
Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patientsZeuzem, S; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N2006126
 
Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B PatientsDiBisceglie A, A; Lai, CL; Gane, E; Chen, YC; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Zeuzem, S; Rasenack, J; Bzowej, N; Han, SH; Naoumov, N; Hwang, SG; Lim, SG; Chao, GC; Fielman, BA; Brown, NA; Study Group The GLOBE,2006179
 
Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs LamivudineLai, CL; Gane, E; Hsu, CW; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, N; Zeuzem, S; Di Bisceglie, A; Chao, GC; Barbara, A; Constance, F; Brown, NA; Study Group The GLOBE.,2006258
 
Adefovir Dipivoxil Therapy for Lamivudine-Resistant Hepatitis B in Pre- and Post-Liver Transplantation PatientsSchiff, ER; Lai, CL; Hadziyannis, S; Neuhaus, P; Terrault, N; Colombo, M; Tillmann, HL; Samuel, D; Zeuzem, S; Lilly, L; Rendina, M; Villeneuve, JP; Lama, N; James, C; Wulfsohn, MS; Namini, H; Westland, C; Xiong, S; Choy, GS; Van Doren, S; Fry, J; Brosgart, CL2003177
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download